Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Adults
I'm PortAI, I can summarize articles.
Vaxcyte Inc. has initiated the OPUS Phase 3 trial for its VAX-31 pneumococcal vaccine, targeting invasive pneumococcal disease and pneumonia in adults. The trial will enroll 4,000 participants and compare VAX-31 to existing vaccines Capvaxive and Prevnar 20. Results are expected in late 2026, with further studies planned for 2026-2027. This AI-generated news is informational and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments